UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience

Nesr, George; Shah, Raakhee; Kyriakou, Charalampia; Sive, Jonathan; Popat, Rakesh; Yong, Kwee; Wisniowski, Brendan; ... Rabin, Neil; + view all (2023) Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience. Leukemia & Lymphoma 10.1080/10428194.2023.2216817. (In press). Green open access

[thumbnail of Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment a single center experience.pdf]
Preview
PDF
Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment a single center experience.pdf - Published Version

Download (1MB) | Preview

Abstract

High dose melphalan (HDM) followed by autologous stem cell transplantation (ASCT) remains the standard consolidation in transplant eligible multiple myeloma (MM) patients. The timing between HDM administration and hematopoietic stem cell return (HSCR) varies among institutions, with a 'rest period' of 48 hours (h) employed by some for patients with renal impairment (RI). We investigated the differences in hematopoietic recovery and HDM toxicity between MM patients with RI who had HSCR after 24 vs 48 h from HDM. Fifty MM patients with RI (48 h group; n = 31 and 24 h group; n = 19) were included. No statistically significant differences were noted in surrogates for hematopoietic recovery and HDM toxicity between both groups. Only one death occurred in the 24 h group. No patients required renal replacement therapy. Therefore, a 24 h period between HDM and AHSC infusion appears safe for MM patients with RI.

Type: Article
Title: Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1080/10428194.2023.2216817
Publisher version: https://doi.org/10.1080/10428194.2023.2216817
Language: English
Additional information: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Keywords: Multiple myeloma, autologous stem cell transplantation, renal impairment
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: https://discovery.ucl.ac.uk/id/eprint/10171411
Downloads since deposit
34Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item